Health
109 items · page 2 of 6
- Thursday, 10 September 2026 · From Zero's Briefs
The 2026 Albert Lasker Basic Medical Research Award was granted on September 9 to the two researchers for the identification of orexin, a peptide that maintains wakefulness, and for the discovery that its deficiency causes uncontrolled sleep in type 1 narcolepsy. Mignot works at Stanford University School of Medicine, Yanagisawa at the University of Tsukuba. The Lasker Foundation notes that approved drugs blocking orexin receptors for insomnia already exist, and that a receptor-2 activator is in advanced development for narcolepsy: it is therefore still under study, not available. Le Monde reports a prevalence of about one person in 2,000 and around 6,000 patients in France (Le Monde; Lasker Foundation).
- Thursday, 10 September 2026 · Analysis
WHO creates special envoy for health resilience while flagging funding crisis
On September 9 the World Health Organization announced the appointment of Vanessa Kerry to a newly created role. In the same weeks the agency launched an initiative on access to mpox vaccines with partners and validated two disease eliminations, in Bhutan and Timor-Leste.
- Thursday, 10 September 2026 · From Zero's Briefs
The eighth meeting of the World Health Organization's intergovernmental working group on the pandemic agreement is scheduled from September 14 to 18, 2026. It is the forum where member states negotiate tools for managing future international health emergencies (WHO, events calendar).
- Wednesday, 9 September 2026 · Analysis
Measles: Bangladesh leads global infections as the Americas move to "very high" risk
A story the morning edition did not tell: WHO surveillance data place South-East Asia as the region with the highest number of confirmed cases in 2026. Bangladesh has recorded over 120,000 suspected cases and nearly 800 deaths by the end of July; the United States recorded 3,134 confirmed cases as of September 3.
- Wednesday, 9 September 2026 · Analysis
Ebola Bundibugyo: ECDC reports 6,686 confirmed cases and 3,226 deaths in DR Congo
The September 7 update reports 82 new confirmed cases and 51 deaths compared to the previous report, with 819 patients in isolation. No approved treatments or vaccines exist for this virus.
- Wednesday, 9 September 2026 · From Zero's Briefs
On September 5, 2026, the World Health Organization released a technical document dedicated to El Niño 2026, summarizing evolving health risks and aiming to support risk assessment, preparedness and anticipatory action at the country and regional level, with attention to vulnerable populations. Single, primary source (WHO).
- Tuesday, 8 September 2026 · Analysis
Parkinson's: positive CHMP opinion for a levodopa/carbidopa formulation
The EMA's committee has recommended authorisation of Hopledo for adults with moderate to severe motor fluctuations. The efficacy data available come from the company holding the marketing authorisation, not from an independent review.
- Tuesday, 8 September 2026 · Analysis
Secondhand smoke, a study estimates 2.71 billion exposed and 1.66 million deaths in 2023
The Global Burden of Disease analysis published on September 8 in The Lancet Public Health covers 204 countries from 1990 to 2023. These are model-based estimates, with the limitations the authors disclose.
- Tuesday, 8 September 2026 · From Zero's Briefs
On September 1, 2026 the World Health Organization published updated emergency guidance on the possible use of Ervebo, the only authorized anti-Ebola vaccine, and the director-general opened a high-level briefing with member states on the response in the Democratic Republic of the Congo (WHO). For the Bundibugyo species there is no approved specific vaccine or treatment; the international emergency was declared on May 16, 2026 (PAHO).
- Tuesday, 8 September 2026 · From Zero's Briefs
At its June 22-25, 2026 meeting, the EMA's committee for human medicinal products recommended the approval of six medicines, including the influenza vaccine Aujemflu for people aged 50 and over and Hopledo for Parkinson's disease. Mounjaro was not recommended for a new indication on reducing cardiovascular risk, although the inclusion of the data in the product information was accepted. In February 12 medicines had been recommended (Pharmaceutical Technology).
- Monday, 7 September 2026 · From Zero's Briefs
On September 1, the World Health Organization published updated emergency guidance on the potential use of Ervebo — described by the organization as the only licensed Ebola vaccine — during outbreaks; on July 27, the WHO had issued a statement on efforts to contain Ebola in the Democratic Republic of the Congo. On September 2, the executive summary with key recommendations from the second edition of the guidelines on reducing the risk of cognitive decline and dementia was published, updating the previous edition. Both documents come from the same institution, cited as the primary source. (WHO, WHO)
- Monday, 7 September 2026 · Analysis
Ebola Bundibugyo in Congo: 6,342 confirmed cases and 3,072 deaths in ECDC data
The European centre's update as of September 3 records 770 patients hospitalized in isolation. For this species of virus, according to WHO, there is no vaccine or specific treatment; the risk to the EU/EEA area is considered very low.
- Monday, 7 September 2026 · From Zero's Briefs
A longitudinal study published in The Lancet reconstructs five decades of pneumococcal meningitis in adults, documenting changes in infection sources, serotype distribution, pneumococcal lineages and antibiotic resistance profiles. The authors point to the predominance of the GPSC12 lineage, associated with higher mortality and more severe outcomes, and stress the need for preventive measures against serotype 3; they also note that the findings require confirmation in larger multicenter cohorts. The only source available is the peer-reviewed journal itself. (The Lancet)
- Sunday, 6 September 2026 · Analysis
Ebola Bundibugyo: ECDC data rise to 6,342 confirmed cases; CDC reports five targets not met
The European update as of September 2 indicates 3,072 deaths and 770 patients in isolation. A note from the US CDC describes the Congolese outbreak as the second-largest ever recorded and finds that none of the five critical response indicators have met their targets.
- Sunday, 6 September 2026 · Analysis
Ebola Bundibugyo, WHO updates emergency guidance on the use of the Ervebo vaccine
The outbreak declared in May in the Democratic Republic of the Congo and Uganda concerns a viral species for which no vaccines or specific treatments exist. The document published on September 1st concerns the potential use of the only authorized Ebola vaccine.
- Sunday, 6 September 2026 · From Zero's Briefs
The Pan American Health Organization published an epidemiological alert on July 1, 2026 concerning seasonal influenza and other respiratory viruses in the southern hemisphere, following an initial alert on April 27 about the start of the season. The same archive includes the March 13 alert on yellow fever and the February 27 alert on the misuse of GLP-1 receptor agonist drugs. The regional alerts run alongside the WHO's Disease Outbreak News.
- Saturday, 5 September 2026 · Analysis
WHO measures global health progress and where it has stalled
New HIV infections down 40% since 2010 and neglected tropical diseases in retreat, but universal health coverage is advancing slowly and the pace of child mortality reduction has fallen by more than 60% since 2015.
- Friday, 4 September 2026 · From Zero's Briefs
The ECDC update of September 2, based on data from the Congolese Ministry of Health as of September 1, indicates 6,250 confirmed cases and 3,039 related deaths in the Bundibugyo virus outbreak that began in May in Ituri, with 869 patients hospitalized in isolation and 1,439 recovered. Compared with the previous report there were 64 new confirmed cases and 32 deaths, with new cases in Ituri (39), North Kivu (20), Haut Uele (4) and Tshopo (1); 89% of identified contacts are under observation. No approved vaccines or specific treatments exist for this species. On September 1, the WHO published updated emergency guidance on the potential use of Ervebo, the only licensed Ebola vaccine, during outbreaks. Sources: ECDC, WHO.
- Friday, 4 September 2026 · Analysis
From September 1st EMA no longer accepts old PDFs for medicine variations
The European Medicines Agency completes the transition to the mandatory electronic form for variation applications for medicines authorised under the centralised procedure. WHO publishes the summary of the second edition of its guidelines on cognitive decline.
- Friday, 4 September 2026 · From Zero's Briefs
In a text released in early September, the World Health Organization again classifies antimicrobial resistance among the leading threats to health and development on a global scale. The point raised by the document concerns inequalities: equity issues, the agency writes, remain insufficiently addressed in policies and practices to counter the phenomenon. The text is published in the organization's news and publications section. The news currently comes from a single source, of an institutional nature (WHO); no independent confirmation available.
Looking for Health news from a specific day?